Quick Takeaways
- David Charles Lubner has 7 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,624,425.
- Recent insider filing activity is available below.
Follow Filing Activity
Follow David Charles Lubner and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original Filing| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | Director | $1,624,425 | -$450,000 | -22% | 20 Jan 2026 |
| CRGX | CARGO Therapeutics, Inc. | Director | 19 Aug 2025 | |||
| DYN | Dyne Therapeutics, Inc. | Director | 30 May 2025 | |||
| IRON | Gemini Therapeutics, Inc. /DE | Director | 04 Oct 2021 | |||
| CBIO | GLYCOMIMETICS INC | Director | 23 Jun 2025 | |||
| PNT | POINT Biopharma Global Inc. | Director | 26 Dec 2023 | |||
| VOR | Vor Biopharma Inc. | Director | 22 May 2025 |
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|